A r t i c l e s Clinical translation of basic cancer research is hindered by several obstacles 1 . One arises from the intrinsic limitations of experimental systems, which may not demonstrate concordance with human studies; for example, conventional two-dimensional (2D) cell culture models do not maintain the interactions of tumor cells with the extracellular matrix (ECM) and the tissue microenvironment, which are essential for tumor pathogenesis 2 . Similarly, animal models are expensive and time-consuming and may not have the resolution and sensitivity required to track the dynamics of cancer progression. In addition, because of species variation, animal models and humans may have different requirements for oncogenic transformation. Another problem stems from the fact that tumors evolve heterogeneously; the large number of passenger mutations they accumulate can confound the identification of driver genes 3,4 . Although highthroughput genetic approaches have facilitated the identification of genome-wide alterations in cancers 5, 6 , testing the role of each gene in cancer pathogenesis in the native environment is a crucial but difficult task, given the large number of low-frequency mutations in most cancer genomes.
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Intestinal organoid systems can be used for modeling both normal and disease tissues [7] [8] [9] . However, these systems usually lack native tissue structures and ECM and thus do not mimic vital aspects of intestinal physiology. Recent technical advances have made it possible to isolate natural cellular matrix with preserved ECM and normal 3D tissue architecture, providing a potentially useful approach for producing more physiologically relevant models of cancer [10] [11] [12] . Ridky et al. 13 have successfully established ex vivo systems recapitulating the normal-neoplasia-invasion sequence with modified human epidermis, oropharynx, esophagus and cervix epithelial cells in a human 3D tissue environment. Here we describe an ex vivo model of the human colon that mimics physiological conditions by first decellularizing normal human colon tissue under conditions that retain the tissue's complete geometry with a well-preserved ECM, relatively integral vascular network and intact muscularis mucosa, then reseeding with primary colonic epithelial cells, endothelial cells and myofibroblasts. We used the model to study colorectal cancer (CRC) progression by recellularizing the colon matrix with epithelial cells carrying mutations in genes known to be important in CRC progression, such as APC and KRAS. Similarly to CRC, this led to the development of neoplasia in situ with little submucosal invasion, whereas reseeding with cells carrying mutant APC and an activating mutation in KRAS (KRAS G12D ) 14 in the context of reduced transforming growth factor-β (TGF-β) signaling 15, 16 led to the development of invasive submucosal tumors. We used the ex vivo model to perform a Sleeping Beauty (SB) transposon mutagenesis screen to identify genes that cooperate with mutant APC in driving invasive neoplasia.
A recellularized human colon model identifies cancer driver genes A r t i c l e s RESULTS Preparation of decellularized human colon matrix Cellular components from fresh normal human colon tissue (~5 cm 3 ) were removed by sodium dodecyl sulfate (SDS) treatment 10 followed by washing with Triton X-100, resulting in the complete decellularization of the colon tissue (Fig. 1a-d) . The DNA content of these acellular colon scaffolds was more than 95% lower than that found in normal colon (Supplementary Table 1 and Supplementary Methods), whereas no differences were observed in the quantities of the four main ECM proteins 17 , glycosaminoglycan, collagen type I, laminin and fibronectin (Supplementary Table 1 and Fig. 1h) .
The decellularized scaffolds successfully preserved the tissue architecture, main vasculature and crypt niches of the original organ ( Fig. 1e-g ). The removal of most cellular components was further confirmed by the observation that F-actin and cellular nuclei were undetectable in decellularized scaffolds by immunohistochemistry (Fig. 1h) .
Recellularization of the acellular human colon matrix A key feature that makes the ex vivo colon model useful for identifying CRC driver genes is that it has a genetically defined epithelium that is free of malignant origins and secondary genetic alterations. To recellularize the acellular colon matrix we first established primary cultures of the three main cellular components of the colon-epithelial cells, endothelial cells and myofibroblasts. Epithelial cells and myofibroblasts cells were obtained from routine colonoscopy patient samples, whereas endothelial cells were purchased from commercial sources. Epithelial cells were grown under conditions normally used for organoids 9 to help retrain their stem cell component and differentiation potential. These cells were then modified with human telomerase reverse transcriptase (hTERT) to prevent premature senescence and ensure their long-term growth potential (Supplementary Fig. 1a ). DNA sequencing of these primary colonic epithelial cells (hCECs) confirmed that they did not carry mutations in hotspot regions of APC, KRAS or TP53 (data not shown). When grown in 3D culture, these hCECs formed organoids with microcrypt-like structures (Supplementary Fig. 1a ) and were capable of self-renewal and multilineage differentiation 18 ( Supplementary Fig. 1b) .
Recellularization of the colon matrix was done in several discrete steps (Fig. 2a) . First, the large bowel mucosa with intact crypt niches and muscularis mucosa was mechanically separated from the submucosa by forceps (Supplementary Fig. 2a,b and Supplementary Video 1). This made it possible to reintroduce the hCECs, endothelial cells and myofibroblasts into their normal physiological locations within the acellular colon matrix (Fig. 2b) . For populating the mucosa, a microinjection pipette was filled with endothelial cells (Supplementary Figs. 2c and 3b and Supplementary Video 2) , and the cells were injected into the mucosa through the side of the tissue (0.1 million/cm 2 ) ( Supplementary Fig. 2d and Supplementary Video 3). After the endothelial cells started to proliferate, hCECs (0.2 million/cm 2 ) were placed on top of the crypt surface and seeded into the crypt niches through gravity precipitation. Finally, colonic myofibroblasts ( Supplementary Fig. 3a ) (0.1 million/cm 2 ) were seeded and grown on the muscularis mucosa, which was exposed through separation from the submucosa. In addition to the muscularis mucosa, the stroma surrounding the colonic crypts in the normal colon also contain myofibroblasts. Owing to technical limitations, however, we were unable to repopulate the mucosa pericryptal with myofibroblasts and focused instead on repopulating the muscularis mucosa layer with colonic myofibroblasts. The ex vivo colon was then generated by assembling together the mucosa and submucosa layers ( Fig. 2b and Supplementary Fig. 2e,f) . The process of decellularization and recellularization preserved native colon ECM and its mechanical and chemical properties (including intestinal fibers composed of laminin and collagen in the correct orientation), composition and microstructure (Supplementary Fig. 4a) . Notably, the recellularized colon matrix retained the ultrastructural elements of the muscularis mucosa-the native barrier for the invasion of the malignant CRC submucosa 19 -which was not substantially different in thickness from that found in native tissues ( Fig. 1g and Supplementary  Fig. 4b,c) . The recellularized ex vivo colon not only was viable but also contained cells expressing LGR5, a stem cell marker in small intestine and colon, in addition to other differentiated cell types normally found in the colon (Supplementary Fig. 5 ). Physiologically similar to native ones, our ex vivo colon crypts contained dynamic proliferation capacity (Supplementary Figs. 5 and 6b) , actively reproduced WNT-β-catenin signaling, which is essential for intestinal homeostasis ( Supplementary Fig. 6a) , and expressed the major mucin protein MUC2 (Supplementary Fig. 6c ), indicative of secretory activity of the recellularized crypts. We also analyzed the growth capacity of the three cell lines in recellularized mucosa by Ki67 staining and observed that endothelial cells were the first cell type undergoing growth dormancy or senescence after the reconstituted mucosa were cultured for 8-10 weeks (data not shown). . DAPI and cytoskeleton protein were undetected in the acellular matrix, whereas the three main ECM proteins were well preserved. Scale bars, 100 µm.
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Establishment of a CRC progression model CRC develops through the stepwise selection of genetic changes. The initiating or gate-keeping mutation is biallelic loss of APC, which occurs in >80% of cases 20 . This is followed by mutations in other genes, such as activating mutations in KRAS at the early-to intermediate-adenoma stages, and loss-offunction mutations in SMAD4 and TP53 at the intermediate-adenoma to adenocarcinoma stages 21, 22 . To determine whether it was possible to transform hCECs into tumor cells, we infected these cells with a lentivirus that expresses a small hairpin RNA that disrupts APC (APC shRNA) and a constitutively active KRAS (KRAS G12D ) ( Supplementary  Fig. 7) . These cells were then subcutaneously injected into immunodeficient mice. Two weeks later, mice were injected intraperitoneally with TGF-β receptor inhibitor (TGF-βRI) 15 to mimic inactivation of TGF-β signaling, which drives CRC progression and particularly submucosal invasion, which can be caused by a simple genetic alteration in this pathway along with mutated APC 23 . Within 6-8 weeks after injection, tumors were visible at 60-80% of the injection sites and showed typical epithelial CRC-like features, including crypt-like lumen structures and microvasculature formation ( Supplementary  Fig. 8 ).
In control experiments using injection of parental hCECs, we did not observe formation of tumors ( Supplementary Fig. 8 ) (Fisher's exact test, P = 0.00025).
On the basis of these findings, we asked whether we could model CRC progression using the ex vivo colon model (Fig. 2a) . Similarly to normal human colon (Fig. 2c) , the acellular colon recellularized with unmodified hCECs formed a single-cell layer in crypt niches, and the cells were tightly attached to the basal membrane and stromal ECM (Fig. 2d) . By contrast, when the acellular colon was recellularized with hCECs expressing APC shRNA (APC-shRNA hCECs), dysplasia was visible in the mucosa epithelium, a phenotype typically seen in early-stage adenomas, with which cells underwent fast proliferation to form multicellular layers and distorted crypt structures with multiluminal fusions (Fig. 2e,f) . These dysplastic lesions formed in only 3 weeks and were restricted to the mucosa layer (P < 0.001, one-way ANOVA). The dysplasia grew larger without invasive events when acellular colon was recellularized with APC-shRNA hCECs in addition to activated KRAS G12D (Fig. 2g,h) . However, when the TGF-β signaling pathway was inhibited in acellular colon recellularized with APC-shRNA hCECs expressing activated KRAS G12D , large adenomas developed, broke through the muscularis mucosa and invaded the submucosa, a key feature of malignant CRC (Fig. 2i-k) (P = 0.0024, one-way ANOVA). This malignant transformation occurred within 4 weeks after onset of the dysplastic lesions that formed with APCshRNA hCECs.
Collectively, these results show that this type of organotypic colon cancer model, developed with human natural matrix and genetically defined primary colon cells, is capable of recapitulating key features of CRC initiation, progression and malignant transition from noninvasive neoplasia to invasive submucosal tumor. The different stages of oncogenic transformation can be generated relatively easily and within weeks in this model, correlating well with histological features All of the recellularized tissues were analyzed after 7 weeks in culture. n = 10 independent matrices; P values determined by one-way ANOVA; error bars indicate mean ± s.e.m.
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A r t i c l e s and avoiding redundant passenger mutations. This ex vivo system can also provide single-cell resolution and time-lapse sensitivity for anatomically tracking and dissecting CRC progression. These qualities make the ex vivo CRC model potentially useful for high-throughput genetic or therapeutic studies.
Identification of genes driving invasive neoplasia
In previous studies, we used SB mutagenesis to model several types of cancer in mice, thereby identifying many novel cancer genes and cancer signaling pathways [24] [25] [26] [27] . Here we extended the SB mutagenesis system to model cancer directly in human tissues. To create an active human SB transposition system covering a broad target range, we made improvements to the transposon used in previous studies 26, 27 . We added GFP and neomycin selection markers, which make it possible to directly select for cells carrying the transposon. In addition to these selection markers, the transposon carries a murine stem cell virus promoter and downstream splice acceptor site, which activate expression of proto-oncogenes, as well as splice acceptor sites in both orientations and bidirectional poly(A) signals, which inactivate tumor suppressor genes. This transposon is thus bifunctional and can both activate cellular proto-oncogenes and inactivate tumor suppressor genes. Finally, we used a more active SB transposase (SB100X) than used previously 28 . Using this modified transposition system, we found that 500 ng transposon plasmid combined with 100 ng transposase plasmid produced the highest enzyme activity while avoiding the effect of overproduction inhibition (OPI) in hCECs 28 ( Supplementary Fig. 9a ). Under these conditions, each transfected hCEC contains an average of 4 ± 3 (s.d.) transposon copies in its genome after 4 weeks of antibiotic selection (Supplementary Fig. 9b ).
To determine whether we could use SB mutagenesis to identify genes driving invasive neoplasia in the ex vivo colon model, we used the modified SB transposition system to mutagenize APC-shRNA hCECs, which we then used to recellularize the acellular colon matrix (Fig. 3a) . Within 6-7 weeks after recellularization, multiple tumors undergoing submucosal invasion could be seen in the recellularized colons, in contrast to those recellularized with unmutagenized APC-shRNA hCECs, which showed little submucosal invasion (Fig. 3b-e) . The average number of tumors undergoing submucosal invasion formed in 10-cm 2 matrix was 5.5 ± 1.9 (s.d.) for mutagenized cells, significantly higher than the average number of 0.83 ± 0.75 for unmutagenized cells (Fig. 3f) (P = 0.002, Student's t-test). SB-based mutagenesis thus appears to affect genes that drive the invasion of APC-mutant cells. Colon tumors in multiple disease stages were also observed in this ex vivo system, and single-cell resolution could be obtained from time-lapse tracking ( Fig. 3g-i) .
To identify genes mutated by SB that promote invasive neoplasia, we excised 21 invasive neoplasias from 15 recellularized colon matrixes by laser-capture microdissection using a procedure that minimizes contamination from adjacent noninvasive tumor tissues (Supplementary Methods). Transposon junction fragments were then amplified by ligation-mediated PCR and the amplification products sequenced by Illumina sequencing 29 . The distribution of read depths at the insertion sites indicated that the majority of insertions represented subclonal insertions. We therefore considered only the top 10% of insertions with the highest read depth to be clonal insertions. We then mapped these Table 2 ). Notably, 17 of the 38 genes have already been implicated as contributing to CRC progression, including TCF7L2, which functions in WNT1 signaling 30, 31 ; MSH2, a DNA mismatch-repair gene 5, 22 ; TWIST2, which is important for the epithelial-to-mesenchymal transition 32 ; JAK1 and STAT3, which function in JAK-STAT signaling 33 ; and DCC, which is commonly deleted in CRC 34 ( Table 1) .
Most of these candidate invasion-driver genes were mutated in a single invasive neoplasia (Supplementary Table 2) . However, six genes (CSTF3, GRM8, KDM2B, LATS2, PAX7 and TCF7L2) were mutated in two invasive neoplasias, and one (PTPRD) was mutated in three invasive neoplasias. In the case of CSTF3, GRM8, KDM2B, PAX7 and TCF7L2, SB was inserted at the same nucleotide site in each invasive neoplasia, indicating that these invasive neoplasias were generated from the same clone of SB-mutagenized cells. For LATS2 and PTPRD, two invasive neoplasias for each gene were identified in which SB was located at different nucleotide sites (Supplementary Table 2) , suggesting that these neoplasias were derived from different clones of SBmutagenized cells. LATS2 encodes a putative serine-threonine kinase that physically interacts with MDM2 to inhibit p53 ubiquitination and promote p53 activation 35, 36 . Expression of PTPRD, which encodes protein-tyrosine phosphatase receptor-delta, is downregulated in highly invasive cancers and has been shown to suppress colon cancer cell migration in coordination with CD44 (ref. 37) . Moreover, 55% of the identified candidate invasion-driver genes (21/38) are mutated in ≥5% human CRC patients and/or show a twofold change in mRNA expression level in CRC patients 5 (Supplementary Table 2 ; RNA-seq data available at http://firebrowse.org. Collectively, these results suggest that insertional mutations in these genes were selected because of their influence on invasive cell growth.
Although the majority of genes identified by SB in solid tumors are tumor suppressor genes, some, such as TWIST2, JAK1, ROCK1 and STAT3 are more likely to be oncogenes on the basis of published studies. However, owing to the limited amounts of invasive tissue obtained from laser-capture microdissection and the potential RNA degradation the procedure may cause, the samples were sufficient for isolating only enough DNA to PCR amplify and sequence transposon insertion sites. It was therefore not possible to determine whether SB insertion in these genes resulted in activation or inactivation of their expression. Because these genes have already been implicated in CRC, we focused our validation studies on the 21 genes identified that have not previously been implicated in CRC.
In initial experiments, we used small interfering RNA (siRNA) to knock down expression of these 21 genes in APC-shRNA hCECs or in SW480 colon cancer cells and measured the effect of the knockdown on cell proliferation, migration and invasion. We used siRNA-mediated knockdown because the majority of genes identified by SB in solid tumors are tumor suppressor genes, and we chose the SW480 cell line because it was derived from an early-stage adenocarcinoma that harbors a mutation in APC. As a positive control, we generated an siRNA against LATS2, a known tumor suppressor identified in the screen, in addition to five randomly chosen negative control genes ( Table 2) . As expected, LATS2 scored positive in vitro cell proliferation and invasion assays, whereas none of the negative control genes scored positive in any assay ( Table 2) . Among the 21 candidate invasion-driver genes, 9 scored positive in one or more assays in hCECs and/or SW480 cells ( Table 2) .
We further validated the 9 genes that scored positive using the ex vivo colon model, along with LATS2 as a positive control and CSTF3, which did not score positive in any of the in vitro assays, as a negative control ( Table 2) . We generated shRNAs to stably downregulate these 11 genes in APC-shRNA hCECs, which we then used to recellularize acellular colon matrices. Among these genes, six (ASXL2, CAMTA1, DDX20, FXR1, MITF and PAX7) significantly promoted submucosal invasion in the recellularized colon model, whereas CSTF3 scored negative ( Supplementary  Fig. 10a,b) . Notably, 85% of invasive neoplasia samples (18/21) harbored at least one mutated candidate invasion-driver gene that was previously implicated in CRC progression and/or functionally validated in this study (Supplementary Table 3 ). In addition, two or more driver genes that were previously implicated in CRC progression and/or functionally validated in this study were identified in 8 of the 21 samples, suggesting potential collaboration among these genes in the invasion events we observed. Collectively, these results suggest that SB mutagenesis in the ex vivo colon model can identify genes important for neoplastic cell invasion.
DISCUSSION
We describe here a tissue-engineering method that enables unbiased forward genetic screens in human tissues under physiologically relevant 
Ability of 21 candidate invasion-driver genes not previously implicated in CRC to increase cell proliferation, migration or invasion in hCEC or SW480 cells after siRNA knockdown. a Positive control; b negative control; +, twofold increase; ++, threefold increase; −, twofold decrease; − −, threefold decrease. n = 4 independent experiments. npg A r t i c l e s conditions. The decellularized human native colon matrix provides major tissue-relevant elements, including complex tissue structure, cell-matrix interactions and physiological colocation of multiple types of differentiated cells. This makes this model more desirable than conventional assays of cell migration or invasion though synthetic Matrigel or collagen layers, which does not mimic real tissues. We used systems that are simpler than the bioreactor-and-medium formula used to generate native functional organs for orthotopic transplantation but fulfill minimal requirements for developing tissue-level tumor models, enabling low-cost and large-scale cancer studies. Currently, only a few animal models have been developed to study malignant events in late-stage CRC 38 . The introduction of pathologically paired genetic elements into the ex vivo model enabled recapitulation of a number of features associated with CRC progression. Malignant transformation also occurred rapidly, within 6-7 weeks after recellularization, further enhancing the value of this ex vivo model as a complement to current cancer models.
Transposon mutagenesis provides an unbiased high-throughput genetic tool for cancer gene discovery 24 . Although SB mutagenesis has been used to model different types of cancers in mice, to our knowledge no previous study has shown that SB is capable of inducing cancer under close-to-native human conditions. Identification of genes driving invasive neoplasia can provide new drug targets and diagnostic markers. However, identifying and studying genes driving malignancy still remains a challenge. The ex vivo colon model provides a tractable system that recapitulates the dynamics of malignant transformation.
In a forward genetic screen, we used this ex vivo model to identify 38 candidate genes driving CRC submucosal invasion through cooperation with mutant APC, demonstrating the effectiveness of the ex vivo model as a functional platform for identifying genes driving tumor cell invasion. One of the genes identified, ASXL2, encodes additional sex combs-like 2 (ASXL2) 39 . ASXL family members are scaffolding proteins that function as epigenetic regulators by recruiting polycomb-group repressor complexes (PRC) and trithorax-group (trxG) activator complexes to DNA. They also have roles in histone modification by assembling transcription factors to specific genetic domains. ASXL2 and ASXL1, along with BRCA1 and YY1, are binding partners of BAP1, a nuclear deubiquitinating enzyme and tumor suppressor that functions mainly during metastasis. Truncation mutations of ASXL2 have been correlated with poor prognosis in prostate cancer, pancreatic cancer and breast cancer. Additionally, ASXL1 is involved in the malignant progression of CRC with microsatellite instability 40 .
Another gene identified, CAMTA1, is a putative tumor suppressor gene in neuronal cancers 41 . Its expression decreases glioblastoma cell growth by stimulating expression of the anti-proliferative peptide NPPA. CAMTA1 also regulates neuroblastoma cell mobility by increasing the expression of β3 tubulin, microtubule-associated protein 2 and neurofilament light chain. Notably, low expression of CAMTA1 is observed frequently in CRC and reported to be an independent indicator for poor patient survival 42 . Consistent with previous findings, both our in vitro and ex vivo functional assays showed significantly increased cell proliferation and invasion in hCECs and SW480 cells with decreased CAMTA1 expression, further indicating a potential tumor-suppressor role for CAMTA1 in CRC malignant transformation.
We observed that 8 of 21 neoplasia samples had mutations in two or more candidate invasion-driver genes previously implicated in CRC progression and/or functionally validated in the present study. These combined mutations may explain how the invasion events occurred. Investigation of the potential cooperative relationships of gene mutations found in the same samples will enable understanding of CRC progression and might eventually help develop novel therapies.
Because of the heterogeneity generated during tumor evolution and the genetic diversity that occurs among individuals, the 38 candidate genes identified here may be specific, to some extent, to the patients from whom the primary colonic epithelial cells were derived. Theoretically, this model system should enable the discovery of a broader range of novel cancer genes by deriving epithelial cells from multiple patients or by generating initial pools of mutagenized cells covering different mutation profiles through varying rounds of SB mutagenesis.
Although mutations in tumors are now routinely identified on a genome-wide scale, elucidating the roles of these genetic alterations in tumorigenesis is still challenging. The ex vivo colon cancer model complements existing cell line systems and animal models for multidimensionally testing the mechanistic roles of recurrent human cancer mutations. Our model and tractable biomimetic systems, such as organoid systems using human and mouse intestinal tissues 7, 8 , will aid understanding of the mechanisms of CRC progression at different stages and development of novel therapeutics. Our model also offers opportunities to create specialized physiological microenvironments for mimicking clinical diseases-for example, by incorporating engineering of vascular networks, the immune system and organ-specific microbes. In addition, our approach might be extended to the generation of other types of ex vivo organs, such as lung, liver, skin and kidney. It could also be applied in other areas of oncology, from developing biomarkers for diagnosis and prognosis to screening drugs, chemicals, pathogens and toxins for personalized medicine.
METHODS
Methods and any associated references are available in the online version of the paper. between different samples). Further analysis was focused on these consensus SB insertion sites. From the distribution of read depth at the insertion sites, it was clear that the majority of the insertion sites resulted from background insertion events or PCR artifacts. We considered the top 10% of the insertion sites with the deepest read counts as clonal insertion sites. We mapped these clonal insertion sites in each sample to the human genome annotation file, RefGene, and picked the sites that were located within 1,000 bp of known transcripts in RefGene to cover both the core promoter and proximal promoter elements 48 . In addition to this, Sanger DNA sequencing of chainterminating dideoxynucleotides (Genewiz) was used to confirm the transposon insertion sites.
Statistical analyses.
Sample sizes for all figures and tables were estimated on the basis of previous studies 38, 49 . For mouse experiments, animals were randomly assigned to experimental groups, and no animals were excluded from the analyses. For each set of experiments, samples were prepared for all experimental arms at the same time. All statistical tests were two-sided. No adjustments were made for multiple comparisons. Investigators were blinded to experimental allocations among different experimental arms for all experiments. For all parametric statistical analyses, data were determined to be normally distributed by the D' Agostino-Pearson test. For all parametric and nonparametric tests, variances were similar between groups being compared.
For comparison between experimental and control groups at specific time points or tissue sites (Figs. 1-3, Supplementary Figs. 4, 6 and 8-10 and Supplementary Table 1) , two-sided Student's t-tests, two-sided MannWhitney (MW) tests and Fisher's exact tests were used. All cells were purchased from ATCC between 2013 and 2015, and cells derived from patients were used within 10 passages and confirmed negative for mycoplasma.
